Vitamin K antagonists or low-molecular weight heparin for venous thromboembolism
28 results
1 - 28
Vitamin K antagonists or low-molecular weight heparin for venous thromboembolism 
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism- Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
- Antithrombotic agents in primary health care
- Deep vein thrombosis
Optimal treatment of acute venous thromboembolism- Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
- Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Anticoagulant therapy for 6 weeks is noninferior to 3 months for provoked VTE in patients younger than 21 years (Kids-DOTT)
- Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Idraparinux effective for DVT but not for PE
- Pentasaccharides for the treatment of deep vein thrombosis
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
- Anticoagulation for people with cancer and central venous catheters